Trial Profile
A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors LIPAC Oncology; TesoRx
- 15 Nov 2021 According to a LIPAC Oncology Media Release, data from this study will be presented at the 22nd Annual Meeting of the Society of Urologic Oncology
- 09 Jun 2021 Positive results from the two-year follow-up published in the TesoRx Media Release.
- 09 Jun 2021 Results presented in a LIPAC Oncology Media Release.